| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Total revenues | $130K+132.1% | $56K-13.8% | $65K-99.8% | $34.0M-15.0% | $40.0M-25.9% | $54.0M |
| Research and development | $13.2M+75.9% | $7.5M+213.2% | $2.4M+133.0% | $1.0M-99.9% | $1.46B-60.8% | $3.71B |
| General and administrative | $11.0M+14.3% | $9.6M+147.1% | $3.9M-34.8% | $6.0M-99.9% | $6.71B-0.2% | $6.72B |
| Total operating expenses | $24.2M+41.2% | $17.1M+172.3% | $6.3M-10.2% | $7.0M-99.9% | $8.16B-21.8% | $10.44B |
| Loss from operations | -$24.0M-40.9% | -$17.0M-444.8% | -$3.1M+55.1% | -$7.0M+99.9% | -$7.93B+21.5% | -$10.10B |
| Interest expense | -$213K+59.5% | -$526K+5.7% | -$558K | — | — | — |
| Change in fair value of convertible promissory notes | $0+100.0% | -$7.0M-231.0% | $5.4M | — | — | — |
| Change in fair value of warrants liabilities | $4.3M-67.6% | $13.2M+1121.5% | $1.1M+578.7% | -$225K | — | — |
| Gain on warrants expiration | $724K | $0 | — | — | — | — |
| Other income, net | $51K-77.6% | $228K-19.4% | $283K+2076.9% | $13K-100.0% | $448.0M+326.7% | $105.0M |
| Total other income, net | $4.8M-17.4% | $5.8M-30.4% | $8.4M+336.8% | -$3.5M+99.5% | -$649.0M-117.1% | -$299.0M |
| Loss before income taxes | -$19.2M-71.3% | -$11.2M | — | — | — | -$11.13B |
| Provision for income taxes | -$18K | $0 | — | — | — | — |
| Net loss | -$19.2M-71.5% | -$11.2M-312.7% | $5.3M+150.1% | -$10.5M+99.9% | -$8.69B+20.9% | -$10.98B |
| Net loss attributable to noncontrolling interest | $33K-50.0% | $66K | $0-100.0% | $60K | — | — |
| NET LOSS ATTRIBUTABLE TO SERINA | -$19.2M-72.2% | -$11.1M-311.4% | $5.3M+150.4% | -$10.5M+99.9% | -$8.68B+20.2% | -$10.87B |
| NET LOSS ATTRIBUTABLE TO SERINA THERAPEUTICS, INC. COMMON STOCKHOLDERS, BASIC | -$19.4M-74.5% | -$11.1M | — | — | — | — |
| NET LOSS ATTRIBUTABLE TO SERINA THERAPEUTICS, INC. COMMON STOCKHOLDERS, DILUTED | -$19.4M-74.5% | -$11.1M | — | — | — | — |
| NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDER, BASIC (in usd per share) | -$1910.00-26.5% | -$1510.00-164.0% | $2360.00+124.3% | -$9700.00-4117.4% | -$230.00 | — |
| NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDER, DILUTED (in usd per share) | -$1910.00-26.5% | -$1510.00-306.8% | $730.00+107.5% | -$9700.00 | — | — |
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING, BASIC (in shares) | 10.2M+38.5% | 7.4M+229.3% | 2.2M+107.1% | 1.1M-97.2% | 37.9M | — |
| WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING, DILUTED (in shares) | 10.2M+38.5% | 7.4M+0.1% | 7.4M+581.3% | 1.1M | — | — |
| Grant revenues | ||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.